We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

A new non-invasive test that uses saliva samples to accurately diagnose cases of prostate cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

The test developed by researchers at the Tehran University of Medical Sciences (Tehran, Iran) could allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

A key challenge in cancer care is the diagnosis of prostate cancer, one of the most common cancers in men. Clinicians currently use invasive biopsies or tests for prostate-specific antigen levels to diagnose prostate cancer in the clinic. But prostate cancer can be hard to spot during the early stages and can be tricky to distinguish from benign prostatic hyperplasia (BPH), a benign enlargement of the prostate that can appear as men age.

In an effort to solve these issues, researchers have developed a new test for prostate cancer that uses saliva samples, which can be collected repeatedly and non-invasively. Their test distinguishes prostate cancer from BPH by testing saliva for eight different microRNAs that either support or suppress tumor growth. The researchers validated their test with saliva samples from 180 men between 45 and 50 years of age, 60 of whom had been diagnosed with prostate cancer using standard methods and 60 of whom had been diagnosed with BPH.

“The advantage of our study is the use of several microRNAs, which have been reported to be detectable in the blood much earlier than the progression of cancer, which makes for a better diagnosis, as well as the use of saliva as a non-invasive biological sample that causes little pain to patients,” said Dr. Jamal Amri of the Tehran University of Medical Sciences.

Related Links:
Tehran University of Medical Sciences 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Mini Vortex Mixer
Vornado
New
PBC Assay
Primary Biliary Cholangitis Assays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.